title: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
abstract: OBJECTIVE
  To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma.
  
  
  METHODS
  A total of 859 patients were randomised to receive oral temozolomide at 150 mg/m(2)/day for seven consecutive days every 2 weeks or dacarbazine, administered as an intravenous infusion at 1000 mg/m(2)/day on day 1 every 3 weeks. The primary endpoint was overall survival (OS), using an intent-to-treat principle. EudraCT number 2004-000654-23 NCI registration number NCT00005052.
  
  
  RESULTS
  Median OS was 9.1 months in the temozolomide arm and 9.4 months in the dacarbazine arm, with a hazard ratio (HR) of 1.00 (95%confidence interval [CI]: 0.86, 1.17; P=0.99). Median progression-free survival (PFS) was 2.3 months in the temozolomide arm and 2.2 months in the dacarbazine arm, with a HR of 0.92 (95%CI: 0.80, 1.06; P=0.27). In patients with measurable disease, overall response rate was higher in the temozolomide arm than in the dacarbazine arm (14.5% versus 9.8%, respectively), but the median duration of response was longer for dacarbazine. The extended schedule, escalated dose temozolomide arm showed more toxicity than the standard dose, single agent dacarbazine arm. The most common non-haematological treatment emergent adverse events reported in both treatment arms were nausea, fatigue and vomiting and constipation.
  
  
  CONCLUSIONS
  Extended schedule escalated dose Temozolomide (7 days on 7 days off) is feasible and has an acceptable safety profile, but does not improve OS and PFS in metastatic melanoma when compared to standard dose dacarbazine.
authors: Academic Unit of Clinical Oncology, University of Nottingham, Nottingham, United Kingdom. poulam.patel@nottingham.ac.uk
authors: Poulam M
authors: PM
authors: Patel
authors: Stefan
authors: S
authors: Suciu
authors: Laurent
authors: L
authors: Mortier
authors: Wim H
authors: WH
authors: Kruit
authors: Caroline
authors: C
authors: Robert
authors: Dirk
authors: D
authors: Schadendorf
authors: Uwe
authors: U
authors: Trefzer
authors: Cornelis J A
authors: CJ
authors: Punt
authors: Reinhard
authors: R
authors: Dummer
authors: Neville
authors: N
authors: Davidson
authors: Juergen
authors: J
authors: Becker
authors: Robert
authors: R
authors: Conry
authors: John A
authors: JA
authors: Thompson
authors: Wen-Jen
authors: WJ
authors: Hwu
authors: Kristel
authors: K
authors: Engelen
authors: Sanjiv S
authors: SS
authors: Agarwala
authors: Ulrich
authors: U
authors: Keilholz
authors: Alexander M M
authors: AM
authors: Eggermont
authors: Alain
authors: A
authors: Spatz